Skip to main content

Table 2 Antimicrobial prescriptions in 2016 and 2018 for cases with aURTDa, FLUTDb and abscesses

From: Antimicrobial prescriptions in cats in Switzerland before and after the introduction of an online antimicrobial stewardship tool

Parameter

aURTDa

FLUTDb

Abscesses

 

2016

2018

2016

2018

2016

2018

Total number of cases

n = 227

n = 244

n = 333

n = 324

n = 216

n = 224

 

% [CI]c

% [CI]c

% [CI]c

% [CI]c

% [CI]c

% [CI]c

Antimicrobial treatment

Yesd

77.1 [71.1–82.4]

67.6 [61.4–73.5]

60.1 [54.6–65.4]

48.8 [43.2–54.4]

95.8 [92.2–98.1]

91.5 [87.1–94.8]

Details of antimicrobial treatment

n = 175

n = 165

n = 200

n = 158

n = 207

n = 205

 

% [CI]c

% [CI]c

% [CI]c

% [CI]c

% [CI]c

% [CI]c

Potentiated aminopenicillin

40.0 [32.7–47.7]

49.1 [41.2–57.0]

60.5 [53.4–67.3]

69.6 [61.8–76.7]

63.8 [56.8–70.3]

63.4 [56.4–70.0]

3rd generation cephalosporin

28.0 [21.5–35.3]

23.6 [17.4–30.9]

25.5 [19.6–32.1]

13.9 [8.9–20.3]

25.1 [19.4–31.6]

20.5 [15.2–26.7]

Aminopenicillin

23.4 [17.4–30.4]

29.1 [22.3–36.7]

11.5 [7.4–16.8]

20.9 [14.8–28.1]

24.2 [18.5–30.6]

32.2 [25.9–39.1]

Fluoroquinolone

4.0 [1.6–8.1]

8.5 [4.7–13.8]

12.5 [8.3–17.9]

15.8 [10.5–22.5]

2.4 [0.8–5.5]

3.4 [1.4–6.9]

Tetracycline

16.0 [10.9–22.3]

20.6 [14.7–27.6]

0.5 [0.0–2.8]

0.0 [0.0–2.3]

0.0 [0.0–1.8]

0.5 [0.0–2.7]

1st generation cephalosporin

0.6 [0.0–3.1]

0.0 [0.0–2.2]

3.0 [1.1–6.4]

1.3 [0.2–4.5]

5.8 [3.0–9.9]

9.3 [5.7–14.1]

Otherse

4.0 [1.6–8.1]

3.6 [1.3–7.7]

0.5 [0.0–2.8]

0.0 [0.0–2.3]

2.4 [0.8–5.5]

3.9 [1.7–7.5]

HPCIAsf

Yesd

33.7 [26.8–41.2]

33.9 [26.8–41.7]

38.0 [31.2–45.1]

29.7 [22.7–37.5]

27.5 [21.6–34.2]

23.9 [18.2–30.3]

Serial/combination therapy

Yesd

14.3 [9.5–20.4]

30.3 [23.4–37.9]

13.0 [8.7–18.5]

19.6 [13.7–26.7]

23.2 [17.6–29.5]

31.7 [25.4–38.6]

Treatment duration (days)g

 

n = 140

n = 127

n = 178

n = 134

n = 153

n = 164

  

Median (range)

Median (range)

Median (range)

Median (range)

Median (range)

Median (range)

 

12 (4–37)

10 (1–21)

13 (1–56)h

9.5 (1–42)h

9 (1–28)

9 (2–28)

  1. Non-overlapping 95% confidence intervals or comparisons with p-values < 0.05 (for treatment duration) are shown in bold; Data from cases from 2016 has been published previously [45]; aaURTD, acute upper respiratory tract disease; bFLUTD, feline lower urinary tract disease; cCI, 95% confidence interval; dValues for the category “no” (reference group) are not shown; eOthers (antimicrobial classes used in ≤ 2% of prescriptions) included amphenicoles, lincosamides, macrolides, penicillins, nitroimidazoles; fHPCIAs, highest priority critically important antimicrobials; gTreatment duration was unknown for numbers not listed (2016: n = 111; 2018: n = 103); hp-value = 0.006